Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:charity
|
| gptkbp:approves |
gptkb:FDA
gptkb:EMA |
| gptkbp:clinical_trial |
Phase IV
Phase III pediatric medicine critical care emergency medicine intensive care transfusion medicine |
| gptkbp:contains |
albumin protein
|
| gptkbp:contraindication |
heart failure
renal impairment severe anemia |
| gptkbp:developed_by |
human plasma
|
| gptkbp:formulation |
5% solution
20% solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Octapharma Albumin
|
| gptkbp:indication |
surgical procedures
cardiopulmonary bypass neonatal care sepsis treatment |
| gptkbp:invention |
Octapharma AG
|
| gptkbp:is_available_on |
intravenous solution
|
| gptkbp:is_used_for |
treatment of liver disease
treatment of burns treatment of hypoalbuminemia volume replacement in shock |
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:produced_by |
Octapharma AG
|
| gptkbp:regulatory_compliance |
gptkb:MHRA
gptkb:WHO TGA |
| gptkbp:side_effect |
headache
nausea allergic reactions fever |
| gptkbp:storage |
room temperature
refrigerated |
| gptkbp:supply_chain |
quality control
distribution network blood donation manufacturing process plasma fractionation |
| gptkbp:bfsParent |
gptkb:Octapharma
|
| gptkbp:bfsLayer |
8
|